Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function.
Parainfluenza virus is a common cause of seasonal upper respiratory tract infections in children and adults. Studies indicate that parainfluenza virus may play an important role in the etiology of respiratory tract infections in lung transplant recipients with an estimated incidence of 5.3 per 100 patients. Parainfluenza virus type 3 is the most frequent serotype in lung transplant patients. The rate of lower respiratory tract infections with parainfluenza virus among lung transplant recipients is between 10 and 66% of cases. In addition, trans-bronchial biopsy at the time of parainfluenza infection shows signs of acute allograft rejection. Subsequently, 32% of patients have been found to have active bronchiolitis obliterans at a median time of 6 months (range 1-14) postviral infection. These findings indicate that parainfluenza virus infections may have long-term implications for lung transplant recipients. Further studies are required to identify the mechanisms of immunomodulation of parainfluenza virus among these patients. In addition, controlled studies are needed to evaluate the efficacy of aerosolized ribavarin in the treatment of parainfluenza virus infection and to determine whether vaccines may be effective in these high-risk patients.
Vilchez
Regis A
RA
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Dauber
James
J
McCurry
Kenneth
K
Iacono
Aldo
A
Kusne
Shimon
S
D000280:Administration, Inhalation; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D016040:Lung Transplantation / Q000276:immunology / Q000706:statistics & numerical data*; D010252:Paramyxoviridae / Q000302:isolation & purification / Q000472:pathogenicity; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D012254:Ribavirin / Q000008:administration & dosage; D012307:Risk Factors; D013577:Syndrome; D023001:Transplantation Tolerance / Q000276:immunology; D016896:Treatment Outcome
D000998:Antiviral Agents; D012254:Ribavirin